RxDoctor Payments DataLook up a doctor →

Steven McCune, MD

Hematology & Oncology · Marietta, GANPI 1043215452

Payments from drug & device makers

$19,502,399in general payments, 2019–2025

Across 2,580 payments — averaging $7559.07 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Merck$7.1M
  • Genentech, Inc.$2.4M
  • E.r. Squibb & Sons, L.L.C.$2.1M
  • Novartis$2M
  • Incyte Corporation$955K
  • Beigene, Ltd.$785K
  • plus $4.1M from 54 others
$28,566in research payments, 2019–2025

Across 25 payments — averaging $1142.66 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

  • Pfizer$24K
  • Eli Lilly$3K
  • F. Hoffmann-la Roche AG$1K
  • Novartis$470
  • E.r. Squibb & Sons, L.L.C.$158

What the payments were for

  • Consulting fees$117,51426%
  • Speaking & faculty fees$290,58165%
  • Travel & lodging$30,2717%
  • Food & beverage$10,9062%
  • Education$2830%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
Merck702$7,087,956
Genentech, Inc.379$2,402,448
E.r. Squibb & Sons, L.L.C.352$2,116,780
Novartis25$2,044,138
Incyte Corporation365$955,445
Beigene, Ltd.23$784,539
Mirati Therapeutics, Inc.46$548,360
AstraZeneca(2 entities)57$527,927
Exelixis Inc.64$519,155
Astrazeneca UK Limited25$412,033
Beone Medicines Ltd.6$377,280
Roche Products Limited38$361,156
Pfizer58$323,253
F. Hoffmann-la Roche AG33$159,127
Eli Lilly15$150,661
EMD Serono, Inc.59$102,563
Seagen Inc.37$90,695
Amgen15$78,308
AbbVie23$74,812
Ipsen Bioscience Inc.15$70,471
Hoffmann-la Roche Limited6$64,773
United Therapeutics Corporation7$56,322
Beigene USA, Inc.25$42,107
GSK32$40,424
Morphosys AG4$31,986
Beone Medicines USA, Inc.10$29,744
Pharmacyclics LLC, An Abbvie Company11$12,784
Ares Trading SA4$11,108
Genentech USA, Inc.12$6,957
Gilead(2 entities)17$4,749
Johnson & Johnson11$2,682
Takeda Pharmaceuticals U.S.A., Inc.5$2,405
Eisai Inc.7$2,044
Bristol Myers Squibb(2 entities)20$1,646
Radius Health, Inc.8$1,189
Janssen Scientific Affairs, LLC1$1,170
Rigel Pharmaceuticals, Inc.2$1,021
Daiichi Sankyo Inc.16$744
Janssen Global Services, LLC1$390
Galvanize Therapeutics, Inc1$149
Regeneron Healthcare Solutions, Inc.5$134
Boehringer Ingelheim4$117
Astellas Pharma US Inc4$95
Ipsen Biopharmaceuticals, Inc3$86
Bayer3$57
Sanofi2$42
Sumitomo Pharma America, Inc.2$38
Pharmaessentia USA Corporation2$36
Agios Pharmaceuticals, Inc.2$35
ADC Therapeutics America, Inc.1$27
Tersera Therapeutics LLC1$27
Stemline Therapeutics Inc.1$26
Recordati_rare_diseases_inc.1$21
Deciphera Pharmaceuticals Inc.1$21
Lilly USA, LLC1$18
Array Biopharma Inc3$18
Jazz Pharmaceuticals Inc.1$17
Syndax Pharmaceuticals, Inc.1$16
Mylan Institutional Inc.1$15
Dendreon Pharmaceuticals LLC1$15

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$19,502,399 in reported general payments places this provider in the 95th percentile of 370 hematology & oncology providers in Georgia.

See all hematology & oncology providers in Georgia

Medicare billing

Part B allowed, 2024
$64,884
Medicare patients
206
Services billed
800

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
BrukinsaZanubrutinib34$388,220
RevlimidLenalidomide11$201,267
EliquisApixaban60$53,671
XareltoRivaroxaban48$36,046
Oxycodone-AcetaminophenOxycodone Hcl/Acetaminophen72$2,256
Oxycodone Hcl55$1,818
Hydrocodone-AcetaminophenHydrocodone/Acetaminophen36$1,416
Hydroxyurea29$1,111
Hydrocortisone13$503
Dexamethasone21$480
Levofloxacin14$471
Morphine Sulfate ErMorphine Sulfate17$436
Prednisone43$405
Ondansetron Hcl46$287
Temazepam27$283

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Beigene USA, Inc.Brukinsa$42,107$388,22034 claims
Bristol Myers SquibbRevlimid$1,646$201,26711 claims
PfizerEliquis$323,253$53,67160 claims
Johnson & JohnsonXarelto$2,682$36,04648 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 370 hematology & oncology providers in Georgia.

Other hematology & oncology in Marietta

See the full list for Georgia

Where these figures come from

Is this you, or does something look wrong? →